BioPlus Acquisition registered to offer 22 million units at $10 each. A unit consists of one Class A ordinary share and one-third of a redeemable warrant; whole warrants exercisable at $11.50.
The new SPAC is targeting the life sciences sector.
BioPlus is led by Chairman Alan Mendelson, a retired partner of Latham & Watkins, where he spearheaded the growth of the partnership’s life sciences practice. Mendelson started his career with Cooley, where he was an associate and partner from 1973 through May 2000, when he joined Latham.
Cantor is sole book-running manager of the offering. The underwriters have an over-allotment option to purchase up to an additional 3.3 million units.
The SPAC said it will apply for a listing on the Nasdaq under BIOS.U. Read more.
